Table 2.

Characteristic features of liver pathology and NAFLD activity score according to the AMLN diet and DPP4i administration at 20th week.

	Chow	AMLN	AMLN + DPP4i
	N = 10	N = 13	N = 10
Steatosis	0.7 ± 0.5	2.8 ± 0.4*	1.9 ± 0.9*#
Lobular inflammation	0.1 ± 0.3	1.8 ± 0.6*	1.1 ± 0.7*#
Hepatocyte ballooning	0.8 ± 0.4	1.6 ± 0.5*	1.3 ± 0.5*
NAFLD activity score	1.6 ± 0.7	6.2 ± 1.3*	4.3 ± 1.9*#

Data are presented as mean ± SEM. *p < 0.05 versus vehicle-treated chow-fed mice. ^#p < 0.05 versus vehicle-treated AMLN-fed mice. Chow, vehicle-treated chow-fed mice; AMLN, vehicle-treated AMLN-fed mice; AMLN + DPP4i, DPP4i-treated (teneligliptin 20 mg/kg of body weight/day by oral gavage for 10 weeks) AMLN-fed mice.

AMLN, Amylin liver NASH model diet; DPP4i, dipeptidyl peptidase-4 inhibitors; NAFLD, non-alcoholic fatty liver disease.